Cited by 310Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisIon Channels and ReceptorsPulmonary Hypertension Research and Treatments

TRPV4 mediates myofibroblast differentiation and pulmonary fibrosis in mice

Open access
Rahaman, Shaik O., Grove, Lisa M., Paruchuri, Sailaja, Southern, Brian D., Abraham, Susamma, Niese, Kathryn A., Scheraga, Rachel G., Ghosh, Sudakshina +6 more·2014·Journal of Clinical Investigation

Abstract

Idiopathic pulmonary fibrosis (IPF) is a fatal fibrotic lung disorder with no effective medical treatments available. The generation of myofibroblasts, which are critical for fibrogenesis, requires both a mechanical signal and activated TGF-β; however, it is not clear how fibroblasts sense and transmit the mechanical signal(s) that promote differentiation into myofibroblasts. As transient receptor potential vanilloid 4 (TRPV4) channels are activated in response to changes in plasma membrane stretch/matrix stiffness, we investigated whether TRPV4 contributes to generation of myofibroblasts and/or experimental lung fibrosis. We determined that TRPV4 activity is upregulated in lung fibroblasts derived from patients with IPF. Moreover, TRPV4-deficient mice were protected from fibrosis. Furthermore, genetic ablation or pharmacological inhibition of TRPV4 function abrogated myofibroblast differentiation, which was restored by TRPV4 reintroduction. TRPV4 channel activity was elevated when cells were plated on matrices of increasing stiffness or on fibrotic lung tissue, and matrix stiffness-dependent myofibroblast differentiation was reduced in response to TRVP4 inhibition. TRPV4 activity modulated TGF-β1-dependent actions in a SMAD-independent manner, enhanced actomyosin remodeling, and increased nuclear translocation of the α-SMA transcription coactivator (MRTF-A). Together, these data indicate that TRPV4 activity mediates pulmonary fibrogenesis and suggest that manipulation of TRPV4 channel activity has potential as a therapeutic approach for fibrotic diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci75331

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 60 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

  1. King TE Jr, Pardo A, Selman M. Idiopathic pulmo- nary fibrosis. Lancet. 2011;378(9807):1949-1961.
  2. Zhu MX, ed. TRP Channels. Boca Raton, Florida, USA: CRC Press; 2011.

Cited by

Sorted by citations

Authors
Rahaman, S. O., Grove, L. M., Paruchuri, S., Southern, B. D., Abraham, S., Niese, K. A., Scheraga, R. G., Ghosh, S., Thodeti, C. K., Zhang, D. X., Moran, M. M., Schilling, W. P., Tschumperlin, D. J., & Olman, M. A.
Affiliations
  • Cleveland Clinic (US)
  • Northeast Ohio Medical University (US)
  • Medical College of Wisconsin (US)
  • MetroHealth Medical Center (US)
Venue
Journal of Clinical Investigation
Published
2014-11-03
Volume
124
Issue
12
Pages
5225-5238
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2093726551
Cited by
310
References
60
Citations by year
2026: 29 · 2025: 31 · 2024: 25 · 2023: 18 · 2022: 45 · 2021: 31 · 2020: 31 · 2019: 17 · 2018: 21 · 2017: 23 · 2016: 21 · 2015: 18
FWCI
16.58
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • American Heart Association
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute (R01HL103553, R01HL096647, R01HL119792, R01HL085324)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Life Sciences › Neuroscience › Sensory Systems › Ion Channels and Receptors
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords
TRPV4, myofibroblast differentiation, pulmonary fibrosis, idiopathic pulmonary fibrosis, mechanotransduction, extracellular matrix stiffness, TGF-β1 signaling, Smad-independent signaling, MRTF-A, lung fibroblasts
MeSH terms
Animals, Antibiotics, Antineoplastic, Bleomycin, Cell Differentiation, Extracellular Matrix, Female, Lung, Mice, Mutant Strains, Pulmonary Fibrosis, Trans-Activators, Up-Regulation, TRPV Cation Channels, Mice, Transforming Growth Factor beta1, Myofibroblasts

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review